Current Liabilities
Other accrued liabilities
Gilead Sciences Other accrued liabilities decreased by 14.0% to $3.40B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 26.3%, from $4.62B to $3.40B. Over 4 years (FY 2021 to FY 2025), Other accrued liabilities shows a downward trend with a -10.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2021
Last reportedQ1 2026May 7, 2026
How to read this metric
Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.
Detailed definition
This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...
Peer comparison
Commonly used as a catch-all for short-term liabilities; varies by industry and business model.
Metric ID:
current_liabilities_other_liabilities_currentHistorical Data
15 periods
| Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.15B | $4.58B | $4.14B | $5.81B | $5.85B | $5.13B | $4.46B | $4.51B | $4.90B | $5.46B | $4.62B | $3.59B | $3.75B | $3.95B | $3.40B |
| QoQ Change | — | -25.5% | -9.6% | +40.3% | +0.7% | -12.3% | -13.0% | +1.0% | +8.6% | +11.6% | -15.5% | -22.3% | +4.6% | +5.4% | -14.0% |
| YoY Change | — | -25.5% | — | — | — | +12.0% | +7.8% | -22.4% | -16.3% | +6.5% | +3.4% | -20.5% | -23.4% | -27.7% | -26.3% |
Range$3.40B – $6.15B
CAGR-15.6%
Avg YoY Growth-12.0%
Median YoY Growth-20.5%
Other accrued liabilities at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's other accrued liabilities?
- Gilead Sciences (GILD) reported other accrued liabilities of $3.40B in Q1 2026.
- How has Gilead Sciences's other accrued liabilities changed year-over-year?
- Gilead Sciences's other accrued liabilities decreased by 26.3% year-over-year, from $4.62B to $3.40B.
- What is the long-term trend for Gilead Sciences's other accrued liabilities?
- Over 4 years (2021 to 2025), Gilead Sciences's other accrued liabilities has grown at a -10.4% compound annual growth rate (CAGR), from $6.15B to $3.95B.
- What does other accrued liabilities mean?
- Miscellaneous short-term debts or obligations not covered by other standard categories.